Lipocine Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2013. The unaudited statements reflect Lipocine Operating as the accounting acquirer in a July 24, 2013 reverse merger and recapitalization with Marathon Bar Corp.; historical financial results are principally those of Lipocine Operating.
Business context
Lipocine is a pre-commercial specialty pharmaceutical company developing oral drug-delivery products focused on men’s and women’s health. Its lead candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT) described as Phase III ready. LPCN 1111, another testosterone candidate, and LPCN 1107, a candidate for prevention of preterm birth, are at earlier stages. The company had generated no product-sale revenue.
Financial results and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2013 and 2012 | $0 in 2013; $7.71 million in 2012 |
| Research and development expense | $1.57 million in 2013; $0.55 million in 2012 | $2.66 million in 2013; $1.70 million in 2012 |
| General and administrative expense | $1.18 million in 2013; $0.47 million in 2012 | $2.60 million in 2013; $1.26 million in 2012 |
| Reverse merger costs | $0.79 million in 2013; none in 2012 | $1.01 million in 2013; none in 2012 |
| Net income (loss) | $(3.48) million in 2013; $(1.01) million in 2012 | $(6.20) million in 2013; $4.76 million in 2012 |
| Basic loss per share | $(0.39) in 2013; $(0.23) in 2012 | $(1.04) in 2013; $1.05 income per share in 2012 |
There were no revenues in the 2013 periods. The 2012 nine-month profit chiefly reflected recognition of $7.52 million in deferred Abbott license revenue after termination of that agreement; it is not a comparable recurring revenue source. Margins are not meaningful given the absence of 2013 revenue.
Cash and cash equivalents were $36.84 million at September 30, 2013, versus $5.38 million at December 31, 2012. Current assets were $37.09 million and current liabilities $1.63 million; total liabilities were $1.63 million, with no debt reported. Nine-month operating cash use was $4.48 million, investing cash use was $1,206, and financing provided $35.94 million. The financing primarily reflected a July common-stock sale; the company reported approximately $35.7 million net proceeds from that sale. Stockholders’ equity was $35.54 million. Outstanding common shares were 10,952,593 at September 30 and 11,056,377 as of November 12.
Material changes and unusual items
- On July 30, the company sold 6,336,664 common shares to accredited investors. The offering materially increased cash and share count.
- R&D expense rose as clinical manufacturing and other external costs increased, particularly for LPCN 1021. G&A expense increased with public-company, merger, professional-service, compensation, and stock-based compensation costs.
- The July reverse merger generated $1.01 million of costs for the first nine months, including shell-company and professional fees.
- In July, Lipocine assigned its cough-and-cold intellectual property and Nexgen agreement to Spriaso, an entity majority-owned by Lipocine directors and affiliates. Lipocine is entitled to 20% of Spriaso’s net proceeds, capped at $10 million, and receives a license back for development outside the cough-and-cold field. The company also agreed to provide Spriaso facilities and certain employee services.
- Management identified two material weaknesses in internal control over financial reporting and concluded disclosure controls were ineffective at September 30. The weaknesses concerned accounting staffing and complex transactions, and accrual-process controls. A new CFO was hired, but the weaknesses remained.
Outlook, commentary, and risks
Management expected to begin LPCN 1021 Phase III enrollment in the fourth quarter of 2013 or early 2014, with results expected in 2015. The filing states the trial had not yet commenced. Management estimated approximately $22 million to complete the LPCN 1021 development process through the planned pivotal trial, related studies, registration batches, and, if appropriate, NDA preparation; actual costs and timing could vary. Management said existing resources were expected to fund projected operating requirements for the foreseeable future, while also stating that additional capital would be needed for future long-term operations.
The company expected significant and increasing expenses and losses as it advances its pipeline and operates as a public company. Key risks include clinical-trial failure or delay, regulatory requirements, manufacturing and supplier dependence, competition in TRT (including potential generics and other oral products), market acceptance and reimbursement, intellectual-property disputes, and the need for future financing. LPCN 1021 may owe Abbott perpetual royalties of 1% or 1.5% on net sales if specified Abbott-era data or formulations are used; the filing describes an initial cap for the first two calendar years after launch, with no cap thereafter.
The filing reports no material legal proceedings and no off-balance-sheet arrangements. It also indicates the company had not filed all reports required during the preceding 12 months. Cash equivalents were primarily short-term; management considered interest-rate exposure not significant.
Important facts for investors to verify
- Whether Phase III enrollment began on the anticipated schedule, and the trial’s design, enrollment, results, and any additional FDA requirements.
- Whether the estimated $22 million LPCN 1021 development cost remains reasonable and whether available cash can support the pipeline and operations as planned.
- The terms and net proceeds of the July equity financing, resulting dilution, and any subsequent share issuance or financing needs.
- Progress in remediating the two material weaknesses, and the implications of the stated reporting-history checkbox.
- The related-party Spriaso transaction, potential royalty value and cap, and any conflicts or obligations arising from the arrangement.